ZNF701 Inhibitors

Chemical inhibitors of ZNF701 target the protein's functionality through various biochemical interactions that directly impede its ability to operate as intended within cellular processes. Disulfiram engages with ZNF701 through its ability to bind to the zinc finger motifs that are critical for the protein's DNA-binding activity. This binding disrupts ZNF701's interaction with DNA, thereby inhibiting its function. Clotrimazole operates on a similar principle; it binds to the zinc finger domains of ZNF701, which are integral to its DNA binding and transcriptional regulation capabilities, thus inhibiting the protein's function. Ebselen introduces modifications to cysteine residues within ZNF701, which can lead to conformational changes that reduce the protein's ability to bind DNA, inhibiting its function. Pyrithione zinc disrupts zinc homeostasis, which is necessary for the maintenance of ZNF701's zinc finger domains and, consequently, its DNA binding capacity.

1,10-Phenanthroline and Clioquinol both act as chelating agents that sequester zinc ions, which are essential for the structural integrity and function of ZNF701's zinc finger domains. This chelation effectively impairs the protein's ability to bind to DNA, thereby inhibiting its function. PDTC, similar to the aforementioned chelators, binds zinc ions and potentially alters the zinc finger domains, which is essential for ZNF701's DNA-binding function. Tiludronate also binds metal ions that could be structurally integral to the function of ZNF701's zinc finger domains, leading to inhibition of its activity. TPCA-1 and Triptolide both inhibit ZNF701 by suppression of NF-κB activation, which is essential for ZNF701's role in regulating gene expression. NSC 95397 inhibits Cdc25 phosphatase, which can lead to inhibition of ZNF701 by affecting phosphorylation status, assuming ZNF701's activity relies on this post-translational modification. Lastly, MG-132 targets the proteasome, and inhibiting this complex can lead to the accumulation of regulatory proteins that may inhibit ZNF701 activity due to imbalances in the signaling pathways in which ZNF701 is involved.